We aimed to determine whether treatment with low-dose IL-2 expands and activates Tregs and reduces CD8+ T cells in the retina, and attenuates retinal inflammation and vasculopathy in murine models of diabetic retinopathy and neovascular retinopathy. The gene discussed is IL2; the disease is diabetic retinopathy.